Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

The acquisition strengthens J&J's focus on neuroscience and expands its portfolio with Caplyta and a promising drug pipeline.

Johnson & Johnson will pay $132 per share in cash, a 39% premium, to acquire Intra-Cellular Therapies, valuing the deal at $14.6 billion.
Intra-Cellular's flagship drug, Caplyta, treats schizophrenia and bipolar depression and has potential for expanded use in major depressive disorder pending FDA approval.
The acquisition aligns with J&J's strategy to grow its neuroscience portfolio, including treatments for Alzheimer's-related agitation and anxiety.
J&J will finance the acquisition through cash and debt, with the deal expected to close later this year pending regulatory and shareholder approvals.
The purchase follows J&J's recent acquisitions in the healthcare sector, totaling over $56 billion in the past five years, to bolster its pharmaceutical and medical device businesses.